Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
OmniAb, Inc.
OABI · SEC Filings
website
89
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery....
Price
5.3
Market Cap
773.06 M
Float
121.62 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about OABI
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
OmniAb, Inc.
OABI · SEC Filings
121.62 M
Float
5.3
Price
773.06 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 30, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 7, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 4, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 4, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2025
News
TYPE
HEADLINE
FILED AT
8-K
OmniAb Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Oct 30, 2026
8-K
OmniAb Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue and Cash Outlook
Aug 6, 2026
8-K
OmniAb, Inc. Appoints Amechi Nwachuku as Chief Operating Officer
Jul 13, 2026
8-K
OmniAb, Inc. Announces Results of 2026 Annual Meeting of Shareholders
Jun 18, 2026
8-K
OmniAb Reports First Quarter 2026 Financial Results and Increases Full-Year 2026 Revenue Guidance
May 7, 2026
8-K
Form 8-K - Current report - Item 2.02 Item 9.01
Mar 4, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B3
UPDATED
Nov 9, 2023
424B3
UPDATED
Nov 2, 2023
424B3
UPDATED
Aug 10, 2023
424B3
UPDATED
Mar 30, 2023
424B3
UPDATED | SHARE RESALE REGISTRATION | Shares amount: 36,450,645 | Share price: $10.00 | Warrants amount: 11,345,489 | Warrants exercise price: $11.50
Feb 10, 2023
425
Form 425 - Prospectuses and communications, business combinations
Oct 3, 2022
Registrations
TYPE
HEADLINE
FILED AT
S-3
Form S-3 - Registration statement under Securities Act of 1933
Sep 12, 2025
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Sep 10, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 18, 2025
POS AM
Form POS AM - Post-Effective amendments for registration statement
Dec 8, 2023
S-3
SHELF | ATM | Offering amount: $300,000,000.00 EFFECTIVE
Dec 8, 2023
POS AM
Form POS AM - Post-Effective amendments for registration statement
May 5, 2023
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 29, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 29, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 26, 2024
Ownerships
TYPE
HEADLINE
FILED AT
4
Love Steven (Reporting)
Nov 2, 2026
SCHEDULE 13G/A
Whitefort Capital Management, LP (Filed by)
Aug 14, 2026
4
Nwachuku Amechi Ekeke (Reporting)
Aug 3, 2026
3
Nwachuku Amechi Ekeke (Reporting)
Jul 13, 2026
4
Bertozzi Carolyn R (Reporting)
Jun 18, 2026
4
Cochran Jennifer R. (Reporting)
Jun 18, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Sep 22, 2025
CORRESP
Form CORRESP - Correspondence
Sep 17, 2025
LETTER
Form UPLOAD - SEC-generated letter
Sep 16, 2025
LETTER
Form UPLOAD - SEC-generated letter
Sep 27, 2024
CORRESP
Form CORRESP - Correspondence
Sep 24, 2024
LETTER
Form UPLOAD - SEC-generated letter
Sep 11, 2024
